D-Deprenyl
Overview
D-Deprenyl, also known as selegiline, is a monoamine oxidase inhibitor (MAOI) that is primarily used in the treatment of Parkinson's disease and major depressive disorder. It is a selective inhibitor of monoamine oxidase B (MAO-B) at lower doses, which makes it useful in increasing dopamine levels in the brain.
Mechanism of Action
D-Deprenyl works by inhibiting the activity of the enzyme monoamine oxidase B, which is responsible for the breakdown of dopamine in the brain. By inhibiting this enzyme, D-Deprenyl increases the availability of dopamine, which is beneficial in conditions like Parkinson's disease where dopamine levels are reduced.
Clinical Uses
D-Deprenyl is primarily used in the management of Parkinson's disease. It is often used as an adjunct therapy to levodopa/carbidopa treatment. In addition to its use in Parkinson's disease, D-Deprenyl is also used in the treatment of major depressive disorder, particularly in patients who do not respond to other treatments.
Side Effects
Common side effects of D-Deprenyl include nausea, dizziness, insomnia, and orthostatic hypotension. At higher doses, it can lose its selectivity for MAO-B and inhibit monoamine oxidase A (MAO-A) as well, which can lead to more severe side effects and dietary restrictions due to the risk of hypertensive crisis.
Pharmacokinetics
D-Deprenyl is well absorbed from the gastrointestinal tract and is metabolized in the liver. It has a relatively long half-life, which allows for once-daily dosing in most patients. The metabolites of D-Deprenyl include amphetamine and methamphetamine, which can contribute to its stimulating effects.
History
D-Deprenyl was first synthesized in the 1960s and was initially investigated for its potential as an antidepressant. Its ability to selectively inhibit MAO-B was discovered later, leading to its use in the treatment of Parkinson's disease.
Related Pages
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
